Citi analyst Eric Joseph assumed coverage and upgraded PTC Therapeutics (NASDAQ: PTCT) from Neutral to Buy with a price target of $108.00 (from $75.00).

For an analyst ratings summary and ratings history on PTC Therapeutics click here. For more ratings news on PTC Therapeutics click here.

Shares of PTC Therapeutics closed at $70.87 yesterday.